Literature DB >> 9653923

Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.

C Krul1, G Hageman.   

Abstract

An isocratic high-performance liquid chromatography procedure was developed for the analysis of five urinary metabolites of caffeine; caffeine or 1,3,7-trimethylxanthine (137X), paraxanthine or 1,7-dimethylxanthine (17X), 1,7-dimethylurate (17U), 1-methylxanthine (1X), 1-methylurate (1U) and 5-acetylamino-6-formylamino-3-methyluracil (AFMU). A standardized procedure was used for oral intake of caffeine and for urine collection. Conditions for sample storage and preparation were optimized, resulting in no detectable loss of caffeine metabolites after storage of the urine samples for four months. Urine samples were extracted with chloroform-2-propanol (4:1, v/v) and separated on a reversed-phase column with acetic acid (33%)-tetrahydrofuran-acetonitrile-water (1:2.5:44:925.5, v/v) as the eluent. Peaks were monitored at 280 nm. Peak heights were measured and the five metabolites were quantified using calibration curves. Cytochrome P4501A2 (CYP1A2) activity was calculated from the molar ratio (AFMU+1X+1U)/17U, N-acetyltransferase (NAT) from the ratio AFMU/1X, XO from the ratio 1U/1X+1U and cytochrome P4502A6 (CYP2A6) from the ratio 17U/(17U+17X+1U+ 1X+AFMU). The inter-assay coefficients of variation ranged from 1.7% for 17U to 5.7% for IX. The intra-individual variation in metabolite ratios determined in two people, with intervals of a few days to several weeks between measurements, ranged from 2. 1% for XO to 11.0% for CYP2A6. Using this procedure, metabolic ratios were determined for four groups of subjects; healthy, non-smoking females using oral contraceptives (OC users, n=5) and non-users (n=5), healthy nonsmoking males (n=9) and children (n=7). Results found in this study were comparable to results reported in the literature for subjects with similar characteristics. A significantly higher CYP1A2 ratio was found for males (4.87+/-0.47) compared to females (3.62+/-0.91: p=0.005, Mann-Whitney). For the other enzyme activities, no significant differences were found between the groups of subjects in this study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653923     DOI: 10.1016/s0378-4347(98)00016-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  11 in total

1.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Authors:  Natasa Djordjevic; Roza Ghotbi; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

2.  Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.

Authors:  J O'Loughlin; G Paradis; W Kim; J DiFranza; G Meshefedjian; E McMillan-Davey; S Wong; J Hanley; R F Tyndale
Journal:  Tob Control       Date:  2004-12       Impact factor: 7.552

Review 3.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Authors:  Natasa Djordjevic; Juan Antonio Carrillo; Guillermo Gervasini; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

5.  Altered xanthine oxidase and N-acetyltransferase activity in obese children.

Authors:  Manoj S Chiney; Sarah J Schwarzenberg; L'aurelle A Johnson
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

6.  A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor.

Authors:  Enda M Byrne; Julie Johnson; Allan F McRae; Dale R Nyholt; Sarah E Medland; Philip R Gehrman; Andrew C Heath; Pamela A F Madden; Grant W Montgomery; Georgia Chenevix-Trench; Nicholas G Martin
Journal:  Sleep       Date:  2012-07-01       Impact factor: 5.849

Review 7.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.

Authors:  Joanne Kotsopoulos; Allison F Vitonis; Kathryn L Terry; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-21       Impact factor: 2.506

9.  Caffeine Consumption Habits of New Zealand Tertiary Students.

Authors:  Saskia Stachyshyn; Ajmol Ali; Carol Wham; Tayla Knightbridge-Eager; Kay Rutherfurd-Markwick
Journal:  Nutrients       Date:  2021-04-28       Impact factor: 5.717

10.  Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.

Authors:  N Amin; E Byrne; J Johnson; G Chenevix-Trench; S Walter; I M Nolte; J M Vink; R Rawal; M Mangino; A Teumer; J C Keers; G Verwoert; S Baumeister; R Biffar; A Petersmann; N Dahmen; A Doering; A Isaacs; L Broer; N R Wray; G W Montgomery; D Levy; B M Psaty; V Gudnason; A Chakravarti; P Sulem; D F Gudbjartsson; L A Kiemeney; U Thorsteinsdottir; K Stefansson; F J A van Rooij; Y S Aulchenko; J J Hottenga; F R Rivadeneira; A Hofman; A G Uitterlinden; C J Hammond; S-Y Shin; A Ikram; J C M Witteman; A C J W Janssens; H Snieder; H Tiemeier; B H R Wolfenbuttel; B A Oostra; A C Heath; E Wichmann; T D Spector; H J Grabe; D I Boomsma; N G Martin; C M van Duijn
Journal:  Mol Psychiatry       Date:  2011-08-30       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.